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Introduction
HyperIgD syndrome is an autoinflammatory disorder
caused by mutations in the MVK gene. While mutations
in most patients follow autosomal recessive inheritance,
we have identified a cohort of patients with recurrent
fevers and only 1 mutation in the MVK gene.
Objectives
To compare clinical features in those with 1 vs. 2 MVK
mutations and to report therapeutic responses in all.
Patients were evaluated at the NIH. Clinical and
laboratory information were collected at each visit.
Methods
Patients were evaluated at the NIH. Clinical and laboratory
information were collected at each visit.
Results
31 pts with mutations in MVK were evaluated: 22 had 2
mutations (21 with V377I and 1 other mutation; 1 with
V203A/H380R), 9 had only 1 mutation after testing the
whole gene (8 with V377I, 1 with I268V). The carrier
frequency of V377I in our control Caucasian population
is 0.3% (2/739). In contrast, in 344 independent cases of
recurrent fever submitted for MVK testing, 8 bore a single
copy of V377I for a frequency of 2.3%.
Clinical or laboratory presentation at the time of a
flare was compared between the 2 groups. There was no
significant difference with regard to age of onset, duration
of flares, frequency of flares, flares after immunizations, GI
symptoms, oral ulcers, sore throat, arthralgia, or adenopa-
thy associated with flares. Rash was more common in pts
with 2 mutations, 20/22 compared to 4/9 in those with
one mutation (p=.01). While there was no difference in
level of IgG, IgA was increased in those with 2 mutations
(452 +230 mg/dl) compared to those with 1 mutation
(230 + 175) (p=.01), as well as level of IgD, (95 + 95, 2
mutations, vs. 8.3 + 7.4, 1 mutation, p=.01)
Since there was no significant difference in clinical
presentation, other than presence of rash and levels of
IgA and IgD, pts were considered together to evaluate
their therapeutic responses. Of 8 pts treated with colchi-
cine, 7 reported no response, 1 reported some improve-
ment. Of 27 pts treated with prednisone at the time of a
flare, 18 noted some improvement; 7 reported either none
or shortening of the interval before next flare. Of 15 pts
receiving montelukast, 4 reported some improvement; 11
reported none. Of 19 pts receiving intermittent anakinra
at the time of a flare, 13 reported some improvement,
3 too early to assess efficacy, and 3 no improvement
including one who developed acute renal failure. 5 pts
received daily anakinra, with 4 reporting some improve-
ment and 1 too early to assess. Of 9 pts receiving etanercept,
4 reported improvement, 5 report none.
Conclusion
Aside for the presence of rash and higher IgA and IgD
levels in those children with 2 MVK mutations, there
are no significant clinical differences between these
groups. There are no clear trends that allow identifica-
tion or predictability of the disease course in children
with either 1 or 2 mutations. Given the higher frequency
of V377I heterozygotes in our patient cohort compared
to the general population, our data suggest that under
some circumstances this may be associated with recur-
rent fevers. Therapeutic options for children with MVK
mutations include intermittent prednisone or anakinra,
either given intermittently or daily; however, not all
patients respond to therapy and there are associated
adverse events in some patients.
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